Three analysts set PLN 86.83 target for Captor Therapeutics stock

Published on 10/20/2026 at 18:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half loss reached PLN 22.76 million versus PLN 20.47 million. Captor Therapeutics stock costs EUR 13.30 in after-hours on October 20, 2026.

Analyst target and market position

Investing.com lists a PLN 86.83 average 12-month target from three analysts on October 17, 2026.
Captor reported a PLN 22.76 million net loss for the first half of 2026, compared with PLN 20.47 million a year earlier.
Captor Therapeutics stock costs EUR 13.30 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST.
The Warsaw listing had a PLN 371.1 million market capitalization and a negative 7.45 price-to-earnings ratio on October 20, 2026.

Captor Therapeutics, PLCPTRT00014, Illustration mit AI erstellt.

Captor Therapeutics (ISIN PLCPTRT00014) has a PLN 86.83 average 12-month price target from three analysts, according to Investing.com on October 17, 2026. The target is 48.17 percent above the Warsaw listing price of PLN 58.60 at the latest quoted level on October 20, 2026. Captor Therapeutics was trading at EUR 13.30 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST.

Analyst target leaves room for debate

The PLN 86.83 consensus sits between a PLN 67.00 low estimate and a PLN 110.00 high estimate, with three analysts included in the survey. That spread of PLN 43.00 shows that the target carries a wide range of assumptions about Captor's clinical development and financing needs.

The average target is a market expectation in PLN, not a euro price target. The German quote therefore provides the trading reference for investors in Germany, while the Warsaw listing remains the relevant home-market quotation for the analyst comparison.

Stock remains below its yearly high

The latest structured quote puts Captor Therapeutics at PLN 58.60, with a 52-week range of PLN 41.60 to PLN 89.20 and volume of 3,792 shares on October 20, 2026. The current level is PLN 30.60 below the 52-week high and PLN 17.00 above the low. The market capitalization was PLN 371.1 million.

The Warsaw Stock Exchange identifies the company as CAPTORTX and assigns it to the biotechnology sector, while GPW lists a reference price of PLN 56.40 and a 52-week range of PLN 42.20 to PLN 87.60 in its October 20, 2026 factsheet.

Losses set the financial backdrop

Captor reported a net loss of PLN 22.8 million for the first half of 2026, compared with a PLN 20.47 million loss a year earlier, according to btlines on September 15, 2026. The comparable figures point to a PLN 2.33 million wider loss, making cash use and clinical milestones important variables for the valuation.

Captor develops targeted protein degradation medicines for oncology, neurodegenerative and autoimmune diseases. BiznesRadar records 6,353,397 shares and describes the company as a Polish-Swiss biopharmaceutical developer.

Captor stock and the next reporting step

The combination of a PLN 86.83 analyst average, a PLN 22.76 million first-half loss and a PLN 371.1 million market value leaves clinical progress as the central valuation variable. The company operates in a development-stage biotechnology model, so earnings remain negative while pipeline programs advance.

Captor Therapeutics was trading at EUR 13.30 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Captor Therapeutics stock.